There are
other complications stemming from body changes in pregnancy.
Not exact matches
A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life - threatening
complication of
stem cell transplants (SCT) used to treat leukemia and
other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.
• In March, a University of Wisconsin team reprogrammed skin fibroblasts into embryonic
stem cells without incorporating the viral or
other foreign DNA that can lead to
complications like cancer.
If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo
stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and
other complications such as Graft vs. Host disease).
By saturating not only the blood but the tissue and
other fluids in the body with oxygen, wounds are able to heal faster through
stem - cell mobilization, bacteria are hindered, swelling and inflammation are drastically reduced and post-operative
complications are mitigated.